Literature DB >> 20147439

Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.

Katalin Jemnitz1, Zsuzsa Veres, László Vereczkey.   

Abstract

Intrahepatic bile acid accumulation due to inhibition of the bile salt export pump (BSEP) has been proposed as a mechanism for drug-induced cholestasis. Many cholestatic drugs do not initiate hepatotoxicity in rats, although they inhibit rat Bsep and cause elevated serum bile acid concentration. In this study, we examined changes in the taurocholate (TC) transport in response to cholestatic drug treatments in human and rat sandwich-cultured hepatocytes. Our experimental setup allows studying the basolateral and canalicular efflux simultaneously, thus comparing drug-induced changes in the vectorial efflux of TC. We found that TC elimination highly differs in human and rat hepatocytes. In human hepatocytes, an equal fraction of TC(uptake) was eliminated by basolateral (34.8%) and canalicular (34.4%) transporters and remained in the cells (30.5%), while in the case of rats, the basolateral transport was dominant (71.7%) and intracellular TC accumulation was negligible (6.9%). The inhibition of BSEP/Bsep resulted in significantly higher intracellular TC(conc) in humans than in rats. The 15-fold difference in intracellular TC(conc) of control in human versus rat hepatocytes was increased 25-fold by troglitazone treatment. MK571 and indomethacin decreased the basolateral efflux and significantly increased the intracellular TC(conc) in rats. In rat hepatocytes, the highest intracellular TC(conc) was observed with cyclosporine A and glibenclamide, which inhibited TC elimination in both directions. Nevertheless, the basolateral transport remained dominant. We conclude that in rats, the higher rate of basolateral bile salt efflux represents an additional protective mechanism in cholestasis, which contributes to species differences in response to hepatotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147439     DOI: 10.1093/toxsci/kfq044

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  15 in total

1.  Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Methods Mol Biol       Date:  2015

Review 2.  Pregnane X receptor and drug-induced liver injury.

Authors:  Yue-Ming Wang; Sergio C Chai; Christopher T Brewer; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-09-25       Impact factor: 4.481

Review 3.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

4.  Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients.

Authors:  Benjamin L Woolbright; Mitchell R McGill; Vincent S Staggs; Robert D Winefield; Parviz Gholami; Mojtaba Olyaee; Matthew R Sharpe; Steven C Curry; William M Lee; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2014-09-19       Impact factor: 4.849

5.  Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.

Authors:  Tracy L Marion; Cassandra H Perry; Robert L St Claire; Wei Yue; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2011-01-24       Impact factor: 4.849

6.  Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.

Authors:  Pamela Bachour-El Azzi; Ahmad Sharanek; Audrey Burban; Ruoya Li; Rémy Le Guével; Ziad Abdel-Razzak; Bruno Stieger; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Toxicol Sci       Date:  2015-02-17       Impact factor: 4.849

7.  Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.

Authors:  Kyunghee Yang; Nathan D Pfeifer; Kathleen Köck; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2015-02-23       Impact factor: 4.030

Review 8.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

Review 9.  The impact of drug transporters on adverse drug reaction.

Authors:  Yan Zhou; Guo-Qiang Zhang; Yu-Hui Wei; Jian-Ping Zhang; Guo-Rong Zhang; Jiang-Xia Ren; Hao-Gang Duan; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-01-22       Impact factor: 2.441

Review 10.  A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.

Authors:  Fozia Noor
Journal:  J Physiol       Date:  2015-11-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.